CRISPR THERAPEUTICS AG Marketable Securities, Unrealized Gain (Loss)
CRISPR THERAPEUTICS AG (CRSP) reported Marketable Securities, Unrealized Gain (Loss) of $8.20 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-06.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2025-05-06
- CRISPR THERAPEUTICS AG marketable securities, unrealized gain (loss) for the quarter ending 2025-03-31 was $8.20M.
- CRISPR THERAPEUTICS AG marketable securities, unrealized gain (loss) for fiscal 2024 was $4.10M.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|
| 2025-03-31 | $8.20M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $4.10M 10-K · filed 2025-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |